Heyholder

This is an amended filing · View original →

‹ Activism Filings

Chong Kun Dang Pharmaceutical Corp. Q3 profit from main business KRW 22.0 billion, up 5.1% from a year earlier

Chong Kun Dang Pharmaceutical Corp.· Periodic ReportAmended

AI summary · Not investment advice

Chong Kun Dang sold KRW 434.3 billion in Q3 and earned KRW 22.0 billion from its main business, up 5.1% from a year earlier and 18.5% from the prior quarter.

Operating profit · 3 months

KRW 22.0 billion

Key facts

Revenue (3 months)
KRW 434.3 billion
Net income (3 months)
KRW 19.3 billion
Period
Q3 (cumulative Jan 1, 2026 ~ Sep 30, 2026)
Revenue (prior-year 3 months)
KRW 429.8 billion
Revenue (year to date)
KRW 1.4 trillion
Operating profit (prior-year 3 months)
KRW 21.0 billion
Operating profit (year to date)
KRW 54.7 billion
Net income (prior-year 3 months)
KRW 20.2 billion
Net income (year to date)
KRW 52.4 billion

Commentary

AI commentary · Not investment advice

What happened

Chong Kun Dang filed its quarterly report with consolidated results for the third quarter. Sales for the latest 3 months were KRW 434.28 billion. That is 1.0% above the same 3 months a year earlier and 9.2% below the previous quarter.

In the company's terms

Operating profit (profit from the core business) for the latest 3 months was KRW 22.05 billion. It rose 5.1% from a year earlier and 18.5% from the previous quarter. Net income (the final profit after taxes and other costs) was KRW 19.32 billion. It fell 4.5% from a year earlier and 5.4% from the previous quarter.

What changes for shareholders

For the year to date, from January 1 to September 30, sales were KRW 1,360.51 billion. Operating profit was KRW 54.75 billion. Net income was KRW 52.36 billion.

Comments

No comments yet

Comments from shareholders will appear here.